Trazodone Add-on in COVID-19-related Selective Serotonin Reuptake Inhibitor-resistant Post-traumatic Stress Disorder in Healthcare Workers: Two Case Reports

• Published in: Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2021, 19(4), , pp.780-785
• Main Authors: Berardis, Domenico De, Fornaro, Michele, Ventriglio, Antonio, Valchera, Alessandro, Vellante, Federica, Pettorruso, Mauro, Martinotti, Giovanni, Fraticelli, Silvia, Giannantonio, Massimo Di
• Format: Article
• Language: English
• Subjects: Case Report; 정신과학
• ISSN: 1738-1088; 2093-4327
• DOI: 10.9758/cpn.2021.19.4.780

COVID-19 represents a significant stress factor for all people worldwide due to several factors, including quarantine, lockdowns, fear of contagion, deaths, and other traumatic events. However, the healthcare workers (HCWs) have paid the higher price of this pandemic in terms of fatalities, contagions, and psychological well-being. Studies suggest that this particular population is at increased risk of developing a severe post-traumatic stress disorder (PTSD). The early diagnosis and timely treatment of PTSD in HCWs may restore well-being and significantly impact health services functioning, reducing burnout, days spent far from work, disrupted personal and team empowerment, and worse job performances. In the present article, we reported on two cases of HCWs directly involved in the treatment of COVID-19 patients who showed selective serotonin reuptake inhibitor-resistant PTSD, which was successfully treated with extended-release trazodone TRZ Contramid Ⓡ add-on.